Table 4.
Baseline Levels of Plasma Markers Before Hepatitis C Virus Direct-Acting Antiviral Treatment in Participants Who Completed Treatment and Had a Sustained Virologic Responsea
| Marker | Geometric Mean (Antilog of SD)b | P Valuec (Cirrhotic vs Noncirrhotic) | Geometric Mean (Antilog of SD)b | P Valuec (Male vs Female Sex) | |||
|---|---|---|---|---|---|---|---|
| Total Group (N = 41) | Cirrhotic (n = 8) | Noncirrhotic (n = 33) | Female Sex (n = 11) | Male Sex (n = 30) | |||
| IP-10, pg/mL | 272 (2.5) | 225 (3.0) | 285 (2.5) | .59 | 237 (2.2) | 286 (2.7) | .53 |
| ATX, ng/mL | 366 (2.0) | 688 (2.0) | 313 (1.8) | .02d | 678 (1.8) | 290 (1.8) | <.001d |
| Mac2BP, ng/mL | 15659 (2.9) | 19640 (2.6) | 14796 (3.1) | .48 | 23045 (2.3) | 13766 (3.1) | .14 |
| IL-6, pg/mL | 1.91 (1.9) | 2.94 (2.1) | 1.73 (1.8) | .08 | 2.93 (2.0) | 1.64 (1.8) | .03d |
| IL-18, pg/mL | 234 (2.8) | 278 (2.9) | 223 (2.8) | .61 | 190 (2.2) | 256 (3.0) | .36 |
| MCP-1, pg/mL | 258 (1.8) | 423 (1.8) | 228 (1.6) | .02d | 231 (1.5) | 269 (1.9) | .37 |
| sCD163, ng/mL | 1312 (2.9) | 836 (3.5) | 1469 (2.7) | .27 | 787 (3.4) | 1593 (2.6) | .11 |
| sCD14, ng/mL | 2275 (2.1) | 1982 (1.8) | 2355 (2.2) | .50 | 2544 (1.8) | 2181 (2.3) | .51 |
Abbreviations: ATX, autotaxin; IL-6, interleukin 6; IL-18, interleukin 18; IP-10, interferon-inducible protein 10; Mac2BP, Mac2-binding protein; MCP-1, monocyte chemoattractant protein 1; sCD14, soluble CD14; sCD163, soluble CD163; SD, standard deviation.
aValues are shown for total group and subgroups by cirrhosis status and by sex at birth.
bAntilog of the SD of the log10-transformed biomarker values.
c P values based on t tests with unequal variance.
dSignificant at P ≤ .05.